Markets
BSE See NSE See 61,685.15
-30.90 (-0.05%)

Strides Shasun gets USFDA approval for Cyproheptadine Hydrochloride Tablets

Nidhi Jani
/ Categories: Trending
Rate this article:
5.0

Strides Shasun’s wholly-owned subsidiary Strides Pharma Global Pte. Ltd. has received approval for Cyproheptadine Hydrochloride Tablets from the United States Food & Drug Administration (USFDA), keeping its ANDA approval momentum intact.

Cyproheptadine Hydrochloride Tablets is an antihistamine used to treat allergy symptoms such as watery eyes, runny nose, sneezing, hives, and itching. According to IQVIA data, the US market for Cyproheptadine Hydrochloride Tablets USP, 4 mg is approximately US$ 20 million.

The company is well-positioned in the market as consistency in compliance indicates minimal regulatory risk in the US market where other peers face difficulties. The company has 74 cumulative ANDA filings with USFDA, out of which 46 ANDAs have been approved and 28 are still awaiting.

Strides Shasun has a global manufacturing footprint with seven manufacturing facilities spread across three continents including five USFDA approved facilities and two facilities for the emerging markets.

On Thursday, the stock of Strides Shasun opened at Rs. 654 per share and touched an intra-day low of Rs. 632, on the BSE.

Previous Article Ten stocks close to their 52-week high
Next Article Ten stocks close to their 52-week low
Please login or register to post comments.

Get A Call From Industry Experts

Send Otp

   I authorize DSIJ Pvt Ltd to contact me. This will override registry on the NDNC.

DSIJ MINDSHARE

L&T Infotech zooms 16.5 per cent on earnings report. Know why?

A major bull rally is being witnessed by the stock on earnings release, with improved attrition rate, double-digit YoY growth in sales and net income have made investors buy the stock.

Subramanian K / Article rating: 4.7
Net sales in Q2 FY22 increased by 8.8 per cent QoQ and 25.6 per cent YoY to Rs.3,767 crore against Rs 2,998 crore in the previous year same...
245Last

Knowledge

245Last